Sanofi/$SNY

13:30
03:10
16:45
06:25
20:00
1D1W1MYTD1Y5YMAX

About Sanofi

Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Ticker

$SNY
Primary listing

Industry

Pharmaceuticals
Headquarters

Employees

82,878

ISIN

US80105N1054

Sanofi Metrics

BasicAdvanced
$117B
8.19
$5.81
0.48
$1.60
3.36%

What the Analysts think about Sanofi

Analyst ratings (Buy, Hold, Sell) for Sanofi stock.

Bulls say / Bears say

Sanofi's acquisition of Vigil Neuroscience for $470 million aims to strengthen its neurological drug portfolio, particularly in Alzheimer's treatment, potentially enhancing future revenue streams. (reuters.com)
The launch of a new vaccine manufacturing facility in Vietnam, in partnership with VNVC, is expected to produce 100 million doses annually by the end of 2027, expanding Sanofi's global production capacity. (reuters.com)
Sanofi's drug Dupixent saw a 29.2% increase in sales, reaching €3.30 billion, indicating strong demand and contributing significantly to the company's revenue growth. (aol.com)
Sanofi's shares hit a 52-week low after issuing a 2024 forecast that fell significantly below expectations, partly due to increased R&D spending and a higher tax rate. (seekingalpha.com)
The company announced it will no longer target a 32% business operating income margin for 2025, raising concerns about long-term profitability. (seekingalpha.com)
Sanofi plans to spin off its consumer products division as a publicly traded entity, which could lead to short-term operational disruptions and investor uncertainty. (seekingalpha.com)
Data summarised monthly by Lightyear AI. Last updated on 27 May 2025.

Sanofi Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Sanofi Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $SNY

Sign up or log in to buy
Capital at risk
Market openADR

Upcoming events

No upcoming events
FAQs